

Investigating the Gut–Brain Interaction in Parkinson's Disease: Neuroinflammation, Microbiome Dysbiosis, and Therapeutic Interventions

A Dissertation

Submitted in partial fulfillment of the requirement of the degree of

Master of Science

in

BIOTECHNOLOGY

by

Huda khanam

24/MSCBIO/60

Under the supervision of

Dr. Kriti Bhandari



**Department of Biotechnology
DELHI TECHNOLOGICAL UNIVERSITY
(Formerly Delhi College of Engineering)
Shahbad Daultpur , Bawana Road , Delhi -110042, India**

May, 2026

ACKNOWLEDGEMENTS

As I submit my M.Sc. dissertation, I want to sincerely thank God for providing me with the fortitude, perseverance, and resolve I needed to do this task effectively. Without the help and direction, I had along the way, this journey would not have been possible. It has been both difficult and rewarding. I am deeply thankful to my mentor, **Dr.Kriti Bhandari**, Department of Biotechnology, Delhi Technological University, for giving me the opportunity to work under his supervision. His guidance, thoughtful suggestions, and consistent encouragement helped me stay focused and improve my work at every stage. His approach toward research and problem-solving has been a valuable learning experience for me, which I will carry forward in my academic and professional journey.

I also want to express my gratitude to my friends and family for their steadfast support. Their encouragement, compassion, and belief in me kept me motivated during the difficult portions of this project. Their presence made this demanding process much more manageable and meaningful.

All things considered, my dissertation has been a tremendous learning experience, and I am appreciative of everyone who helped me finish it, whether directly or indirectly.

HUDA
24/MSCBIO/60



DELHI TECHNOLOGICAL UNIVERSITY

(Formerly Delhi college of Engineering)
Shahbad Daulatpur, Main Bawana Road, Delhi-42

DECLARATION

I, Huda, 24/MSCBIO/60 hereby certify that the work which is being presented in the thesis entitled “Investigating the Gut–Brain Interaction in Parkinson's Disease: Neuroinflammation, Microbiome Dysbiosis, and Therapeutic Intervention” in partial fulfillment of the requirements for the award of the Degree of Master of Science , submitted in the Department of Biotechnology , Delhi Technological University in an authentic record of my own work carried out during the period from 2024 to 2026 under the supervision of Dr. Kriti Bhandari.

The matter presented in the thesis has not been submitted by me for the award of any other degree of this or any other Institute.

Candidate’s Signature



DELHI TECHNOLOGICAL UNIVERSITY

(Formerly Delhi college of Engineering)
Shahbad Daulatpur, Main Bawana Road, Delhi-42

CERTIFICATE BY THE SUPERVISOR

This is to certify that the Dissertation project titled “Investigating the Gut–Brain Interaction in Parkinson's Disease: Neuroinflammation, Microbiome Dysbiosis, and Therapeutic Interventions ” which is being submitted by Huda Khanam 24/MSCBIO/60 , Department of Biotechnology , Delhi Technological University , Delhi in partial fulfillment of the requirement for the award of the degree of Master of Science is a record of the work carried out by the student under my supervision. To the best of my knowledge, this work has not been submitted in part or full for any Degree or Diploma to this University or elsewhere.

Date:

Prof. Yasha Hasija
Head of Department
Department of Biotechnology
Delhi Technological University

Dr. Kriti Bhandari
Supervisor
Department of Biotechnology
Delhi Technological University

“ Investigating the Gut–Brain Interaction in Parkinson's Disease: Neuroinflammation, Microbiome Dysbiosis, and Therapeutic Interventions ”

HUDA KHANAM
24/MSCBIO/60

ABSTRACT

Aim: An aging population is predicted to increase the global burden of Parkinson's disease (PD), a neurodegenerative disorder that progresses over time and manifests in both motor and non-motor ways. There is mounting evidence that the gut-brain axis (GBA) mediates PD development from sites other than the central nervous system (CNS), including the gastrointestinal tract. This review compiles the most recent findings on the function of gut microbiome dysbiosis in Parkinson's disease, including its impact on neurodegenerative processes related to the immune system, neuroendocrine systems, and metabolism. Patients with PD typically exhibit changes in the composition of their gut microbiome, including elevated pro-inflammatory taxa and decreased numbers of bacteria that produce short-chain fatty acids (SCFAs). These changes are linked with disruption of gut barrier function, intestinal inflammation and disturbance of neurotransmitter metabolism. When looking at it from a scientific perspective, dysbiosis can cause α -synuclein misfolding and propagation, inflammation in the nervous system, and problems with the kynurenine pathway's metabolism of the amino acid tryptophan. Thanks to developments in shotgun metagenomics, which have increased our understanding of disease-associated pathways, high-resolution functional profiling of microbial communities is now feasible. Furthermore, prodromal symptoms, such as REM sleep behavior disorder, were similarly associated with microbiome changes, suggesting a potential for early diagnosis. Competing, though still in their infancy, therapies that target the microbiome include fecal microbiota transplantation, probiotics, and prebiotics. More longitudinal and mechanistic research into the gut microbiome is necessary since it may one day serve as a biomarker for Parkinson disease and a target for treatments.

Keywords : *Parkinson's Disease , Gut-Brain Axis , Gut Microbiome Dysbiosis , α -Synuclein Pathology , Short-Chain Fatty Acids (SCFAs)*

LIST OF PUBLICATIONS

1.Review Paper

Title of paper - **"MICROBIOME-DRIVEN NEUROBIOLOGY TO UNDERSTANDING OF THE GUT-BRAIN COMMUNICATION NETWORK"**

Author Names - Huda and Dr. Kriti Bhandari

Name of the Journal - "International Journal of Innovative Science and Research Technology"

Date of submission – 15 April, 2026

Indexing – Google Scholar, ResearchGate, Semantic Scholar, and SJIFactor.com

Status of paper – Accepted

Date of Acceptance – 6 May, 2026

TABLE OF CONTENTS

Title	i
Acknowledgement	ii
Declaration	iii
Supervisor's certificate	iv
Abstract	v
List of publications	vi
List of Figures	viii
List of Tables	viii
Abbreviations	ix
1. Introduction	1
2. Literature Review	2
<i>2.1 Gut-Brain Axis: Architecture and Communication</i>	2
2.2 Microbial Metabolites and Immune Dysregulation in Parkinson Disease	2
2.3 Description of Gut-Brain Axis (GBA)	3
2.4 Immune pathway and Neuroinflammation	4
2.5 Evidence of gut microbiome dysbiosis in PD	6
2.6 Coherent Microbial Patterns Across Studies	8
2.7 Practical Significance of SCFA-Producing Bacteria	10
2.8 Confirming Clinical and Metabolic Evidence	12
2.8.1 Akkermansia muciniphila's role in health and disease	13
2.8.2 Shotgun Metagenomics and Functional Evidence	14
2.8.3 Prodromal Microbiome Changes and Early Disease Signs	15
2.8.4 Role of Gastrointestinal Dysfunction in Early PD Pathogenesis	16
2.9 Mechanistic Pathways: From Gut Dysbiosis to Dopaminergic Neurodegeneration	
3. Methodology	
3.1 The methodology for Shotgun Metagenomics of the Gut Microbiome	17
3.2 Sample Collection and Preservation	19
3.3 DNA Extraction method	21
3.4 DNA Fragmentation and Library Preparation	23
3.5 Sequencing Platform and Depth	24
4. Results and Discussion	26-27
5. Conclusion	27
References	28-31

LIST OF FIGURES

S.NO.	Title of Figures	Page Number
1	The Microbiota-Gut-Brain Axis: Its Bidirectional Nature and Clinical Applications. The figure demonstrates how the gut microbiome interacts with the central nervous system through different mechanisms, including vagus nerve stimulation, circulation, and immune responses.	4

LIST OF TABLES

S.NO.	Title of Table	Page Number
1	Table 1: Pathways Associated with Parkinson's Disease and Gut Dysbiosis	5
2	Table 2 : Functional Roles of Key Gut bacteria in Parkinson Disease Pathogenesis	17

LIST OF ABBREVIATIONS

PD	Parkinson's Disease
GBA	Gut-Brain Axis
CNS	Central Nervous System
ENS	Enteric Nervous System
ANS	Autonomic Nervous System
HPA	Hypothalamic-Pituitary-Adrenal Axis
REM	Rapid Eye Movement
SCFA	Short-Chain Fatty Acid
LPP	Lipopolysaccharide
TNF- α	Tumor Necrosis Factor Alpha
IL-1 β	Interleukin-1 Beta
IL-6	Interleukin-6
A-synuclein	Alpha-Synuclein
BBB	Blood-Brain Barrier
GAA	Gamma-Aminobutyric Acid
RBD	REM Sleep Behaviour Disorder
iRBD	Idiopathic REM Sleep Behaviour Disorder
NF- κ B	Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells
FMT	Fecal Microbiota Transplantation
WGS	Whole Genome Sequencing
WMS	Whole Metagenome Shotgun Sequencing
16S rRNA	16S Ribosomal Ribonucleic Acid
DNA	Deoxyribonucleic Acid
RNA	Ribonucleic Acid
MAG	Metagenome-Assembled Genomes
OTU	Operational Taxonomic Units
ASV	Amplicon Sequence Variants
PCR	Polymerase Chain Reaction
BDNA	Brain-Derived Neurotrophic Factor
GLP-1	Glucagon-Like Peptide-1

PYY	Peptide YY
FFAR	Free Fatty Acid Receptor
IDO	Indoleamine 2,3-Dioxygenase
TDO	Tryptophan 2,3-Dioxygenase
IPA	Indole-3-Propionic Acid

1. INTRODUCTION

Parkinson disease (PD) is the second most common neurodegenerative disorder in the world and is expected to double by 2040 with aging populations overall affecting about 10 million people globally [1]. PD is a disorder with intraneuronal accumulation of misfolded α -synuclein protein aggregates (Lewy bodies and Lewy neurites) and the cardinal motor features of PD are bradykinesia, resting tremor, rigidity, and postural instability [2]. The disease load is far beyond its motor appearance, however, as are non-motor symptoms such as rapid eye movement (REM) sleep behaviour disorder, constipation, anosmia, depression, anxiety, cognitive impairment and autonomic dysfunction, which are often seen in patients for decades before the beginning of motor symptoms and account for a significant proportion of disability.

This prevailing neuropathological staging model by Braak and colleagues helped redefine the pathogenesis of PD, indicating that the processing of α -synuclein pathology does not start in the substantia nigra, but rather first occurs in the peripheral nervous system in the ENS and olfactory bulb and then travels in a caudal-to-rostral fashion through the brainstem via the vagus nerve and ultimately to the midbrain [3].

This “First Body” hypothesis of PD, which places the gastrointestinal tract and its microbial ecosystem as possible starting points for neurodegeneration and has sparked an explosion of research on gut microbiota as a pathogenic factor in, and target for, PD. This present review encompasses the available evidence reinforcing the gut-brain axis as one of the key mechanisms by which gut microbiome dysbiosis contributes to PD pathogenesis, highlights some of the mechanistic pathways involved, reviews methodological approaches used in gut microbiome research and provides thoughts on potential translation into biomarker development and treatment [4].

OBJECTIVE

1. To study changes in gut microbiota in PD patients. Know which taxa of bacteria are reduced (producers of SCFAs) and increased (pro-inflammatory bacteria).
2. To assess effect of microbial metabolites on neurodegeneration. Pay attention to short-chain fatty acids (SCFAs), neurotransmitter precursors and their role in inflammation and neuronal survival.
3. To investigate the mechanisms that connect gut dysbiosis to progressive PD. Research on aggregation of α -synuclein, neuroinflammation, and dysfunction of the intestinal barrier.
4. To investigate the gut-brain axis in PD Pathophysiology. Analyze neural (vagus nerve), immune, endocrine and metabolic communication. The interaction between gut microbiota and dopamine metabolism is explored to determine its relationship.
5. Explore the effect of microbial changes on vitamin synthesis (B6, B1, folate) and

dopamine production. With the aim of assessing gut permeability and inflammatory markers in PD Discuss the correlation between disease severity, “leaky gut,” LPS and cytokines.

6. “In search for early biomarkers of PD Investigate microbiome alterations in prodromal state to identify early diagnosis. To review the new therapeutic approaches that arise in the microbiome.

7. Discuss the future of probiotics, prebiotics and fecal microbiota transplantation (FMT) in the treatment of PD.

2. LITERATURE REVIEW

2.1 Gut-Brain Axis: Architecture and Communication Pathways

The gut-brain axis is a multifaceted bidirectional communication network between the central nervous system (CNS), enteric nervous system, ANS, hypothalamic-pituitary-adrenal (HPA) axis, and the immune and endocrine system in the intestine [5]. This network allows for bidirectional communication from gut to brain and back again via at least four different anatomically and functionally distinct pathways, with each pathway showing relevance to PD pathogenesis. The vagus nerve is the major afferent pathway linking gut-to-brain communication, consisting of ~80–90% sensory fibres from the gastrointestinal tract to the nucleus tractus solitarius in the brainstem [6] .

Vagal afferents innervate the enteroendocrine cells, enterochromaffin cells and the enteric neurons and are profoundly sensitive to luminal microbial metabolites, such as short-chain fatty acids, secondary bile acids and neuropeptides produced by the gut microbiome [7] .

The epidemiological support for the vagal route of α -synuclein propagation from gut to brain is overwhelming, with the near 15,000 patients from the Danish registry study showing a significantly reduced long-term risk of developing PD in patients with truncal vagotomy [8] .

The neuroendocrine route refers to the gut microbiota synthesis of neuroactive metabolites and/or neurotransmitter precursors that either cross the blood-brain barrier or are delivered peripherally to sensory neurons. In the body, about 90% of the serotonin is synthesized in the gut by enterochromaffin cells, which is regulated by microbial metabolites such as short chain fatty acids and secondary bile acids [9] . Many aspects of the disruption of serotonergic signalling in PD have been found and relate to non-motor symptoms such as depression and constipation [10] .

2.1.1 Microbial Metabolites and Immune Dysregulation in Parkinson Disease GBA

The gut microbial enzyme activity is well-known to strongly regulate the kynurenine pathway of tryptophan catabolism that produces both neuroprotective (kynurenic acid) and neurotoxic (quinolinic acid) metabolites, the ratio of which is altered in PD [11].

Moreover, the short-chain fatty acids such as butyrate and propionate, and the dopamine precursors, as well as GABA produced by microbes, regulate blood-brain barrier integrity and neuroinflammation pathways that are relevant to survival of dopaminergic neurons [12].

The role of immunology in the pathogenesis of PD is gaining more and more significance. Intestinal barrier dysfunction (leaky gut) leads to the entry of bacterial products such as LPS and flagellin into the systemic circulation resulting in peripheral and neuroinflammation [13].

Plasma levels of LPS, gut permeabilization markers (zonulin and fatty acid binding protein-2), and pro-inflammatory cytokines (TNF- α , IL-1 β , IL-6) have been consistently found in PD patients compared to controls, and such inflammatory markers have been shown to be correlated with disease severity and duration [14].

In PD, microglia in the substantia nigra are activated and peripheral LPS exposure primes them to be activated, implicating a mechanistic relationship between gut barrier dysfunction, systemic LPS/endotoxaemia and neuroinflammatory dopaminergic cell death [15].

The enteric nervous system is considered a fourth, local acting arm of the GBA. The ENS has 200-600 million neurons, similar to the number of neurons in the spinal cord, and regulates gastrointestinal motility, secretion and immune function on its own to a large extent without input from the CNS [16].

It has been proven that Parkinson's disease patients have Lewy body pathology in the extraspinal nervous system (ENS), which includes phosphorylated α -SYN deposits in neurons of the myenteric and submucosal plexuses, even before the substantia nigra is involved. In fact, some studies have shown that ENS Lewy body pathology can occur in patients up to 20 years before motor symptoms begin. Colonic biopsy of submucosal neurons may serve as a biomarker for the prodromal stage of PD, before clinical motor manifestation, according to some of these arguments [17]. Genetic and environmental factors interact to predispose and modulate disease and symptoms [7].

2.1.2 Description of Gut-Brain Axis (GBA)

- The gut-brain axis is a multifaceted bidirectional communication network between the central nervous system (CNS), enteric nervous system, ANS, hypothalamic-pituitary-adrenal (HPA) axis, and immune and endocrine systems in the intestine [18].
- This network allows bidirectional communication between the gut and brain.
- Communication occurs via at least four anatomically and functionally distinct pathways.
- Each pathway is relevant to the pathogenesis of Parkinson's disease (PD). Immune System Dysregulation

Figure 1. The Microbiota-Gut-Brain Axis: Its Bidirectional Nature and Clinical Applications. The figure demonstrates how the gut microbiome interacts with the central nervous system through different mechanisms, including vagus nerve stimulation, circulation, and immune responses.




Table 1: Pathways Associated with Parkinson's Disease and Gut Dysbiosis

Pathway	Key Components	Mechanism	Impact on PD
Neural Pathway	Vagus nerve, enteric nervous system (ENS)	Misfolded α -synuclein passes via vagal channels from the gut to the brain.	Lewy body spread and progressive neurodegeneration
Immune Pathway	LPS, cytokines (TNF- α , IL-1 β , IL-6), microglia	As a result of gut permeability, bacterial endotoxins can enter the bloodstream and cause neuroinflammation.	Dopaminergic neuronal death
Neuroendocrine Pathway	Serotonin, dopamine precursors, GABA	Neurotransmitter production and signaling are regulated by gut microorganisms.	Non-motor symptoms like constipation and depression
SCFA Signaling	Butyrate, acetate, propionate	Microglial activation, neuroprotection, and BBB integrity are all regulated by SCFAs.	Inflammation is a result of decreased SCFA levels.
Kynurenine Pathway	Kynurenine acid, quinolinic acid	The balance is shifted toward neurotoxic metabolites by altered tryptophan metabolism.	Neuronal injury and excitotoxicity

Neural Pathway: Vagus Nerve**Role of the Vagus Nerve**

- The vagus nerve is the major afferent pathway linking gut-brain communication.
- It consists of approximately 80–90% sensory fibers from the gastrointestinal tract to the nucleus tractus solitarius in the brainstem [19].
- Innervation and Sensitivity

Vagal afferents innervate the following

1. Enteroendocrine cells
2. Enterochromaffin cells
3. Enteric neurons

These fibers are profoundly sensitive to luminal microbial metabolites, such as:

1. Short-chain fatty acids
2. Secondary bile acids
3. Neuropeptides produced by the gut microbiome

Evidence for α -Synuclein Propagation

- Epidemiological support for the vagal route of α -synuclein propagation from the gut to the brain is overwhelming.
The Danish registry study involving nearly 15,000 patients showed that:

Significantly reduced long-term risk of developing PD disease in patients with truncal vagotomy.

- Hazard Ratio: 0.53

Neuroendocrine Pathway

Microbial Production of Neuroactive Compounds

The neuroendocrine route refers to the gut microbiota synthesis of

1. Neuroactive metabolites
2. Neurotransmitter precursors

These compounds either:

1. Cross the blood-brain barrier
2. They are delivered peripherally to sensory neurons. [20]

Serotonin Production

Approximately 90% of serotonin is synthesized in the gut by enterochromaffin cells.

Serotonin synthesis is regulated by microbial metabolites, such as:

- Short-chain fatty acids
- Secondary bile acids [21]

Serotonergic Dysfunction in PD

- Disruption of serotonergic signalling in PD is related to non-motor symptoms such as:
- Depression
- Constipation [22]

Kynurenine Pathway

Gut microbial enzyme activity strongly regulates the kynurenine pathway of tryptophan catabolism.

- The pathway produces:
 1. Neuroprotective metabolite: kynurenic acid
 2. Neurotoxic metabolite: quinolinic acid

The ratios of these metabolites are altered in patients with PD [23].

Other Microbial Metabolites

Short-chain fatty acids, such as

1. Butyrate
2. Propionate

Dopamine precursors and GABA production by microbes

1. Regulate blood-brain barrier integrity
2. Regulate neuroinflammation pathways
3. Influence survival of dopaminergic neurons [24]

2.1.3 Immune Pathway and Neuroinflammation

Intestinal Barrier Dysfunction

Intestinal barrier dysfunction (“leaky gut”) leads to the entry of bacterial products into the systemic circulation.

“Important bacterial products include:

1. Lipopolysaccharide (LPS)
2. Flagellin

This results in:

1. Peripheral inflammation
2. Neuroinflammation

Inflammatory Markers in PD

- Increased plasma levels have been observed in patients with PD:
 1. LPS
 2. Zonulin
 3. Fatty acid binding protein-2
 4. TNF- α
 5. IL-1 β
 6. IL-6

These inflammatory markers correlate with:

1. Disease severity
2. Disease duration

Microglial Activation

- Microglia in the substantia nigra are activated in patients with PD.
- Peripheral LPS exposure primes microglial activation.
- This suggests a mechanistic relationship between the following:
 1. Gut barrier dysfunction
 2. Systemic LPS/endotoxaemia
 3. Neuroinflammatory dopaminergic cell death [25]

2.1.4 Enteric Nervous System (ENS)

Characteristics of ENS

- The ENS is considered the fourth, locally acting arm of the GBA.
- The ENS contains 200–600 million neurons.
- This number is similar to the number of neurons present in the spinal cord [26]

Functions of ENS

- Regulates:
 1. Gastrointestinal motility
 2. Secretion
 3. Immune function
- Functions are largely independent of CNS input.

Lewy Body Pathology in ENS

- Lewy body pathology in the ENS includes:
 - Phosphorylated α -SYN deposits
 - Deposits in neurons of:

- Myenteric plexus
- Submucosal plexus
- Confirmed in patients with PD before substantia nigra involvement.

Early Appearance of ENS Pathology

Some studies have reported ENS Lewy body pathology occurring in:

1. Up to 20 years before motor symptom onset [27].
 2. Biomarker Potential
- Colonic biopsies of submucosal neurons may serve as:
 1. A biomarker for PD prodromal stage
 2. Detection before clinical motor manifestation [28]

2.2 Evidence of gut microbiome dysbiosis in PD

This is a cross-sectional study of compositional changes. The hypothesis of gut microbiome alteration in PD started to be supported by the first major study of faecal microbiota composition using 454 pyrosequencing of the V1–V3 hypervariable region of the 16S rRNA gene, on a total of 72 PD patients and 72 healthy controls. They found a relative decrease in Prevotellaceae, a family that synthesizes folate and thiamine, which are metabolites involved in dopamine synthesis, in PD patients (77% decrease), and that abundance of Enterobacteriaceae was positively correlated with postural instability and pace difficulty [29].

2.3 Coherent Microbial Patterns Across Studies

Almost all subsequent research on the PD microbiome cites this study, which laid the groundwork for GBA studies on PD. Over the next decade, a plethora of cross-sectional 16S rRNA and shotgun metagenomic studies came out, confirming microbiome changes in a wide variety of cohorts from different parts of the world and different ethnic backgrounds. However, there were notable differences in methodology across studies due to differences in DNA extraction, hypervariable region selection, bioinformatic pipelines, and cohort makeup. Reduced relative abundance of SCFA-producing bacteria (e.g., *Faecalibacterium prausnitzii*, *Roseburia intestinalis*, and *Blautia* spp. from the Lachnospiraceae and Ruminococcaceae families) and increased relative abundance of pro-inflammatory Gram-negative bacteria (e.g., Enterobacteriaceae, *Akkermansia muciniphila*, and *Ralstonia* spp.) is the most consistently replicated finding across separate cohorts [30].

2.4 Practical Significance of SCFA-Producing Bacteria

Especially, the decrease in *Faecalibacterium prausnitzii*, which has been shown to have anti-inflammatory effects, should be emphasized. This strictly anaerobic butyrate-producing species can make up as much as 5% of the healthy adult gut microbiome, and has been shown to have strong antilipolytic properties through inhibition of NF- κ B signalling using butyrate, the

induction of differentiation of regulatory T cells, and maintaining the integrity of the intestinal epithelial barrier [31].

Butyrate has also been shown to have neuroprotective effects in animal models of dopaminergic neurodegeneration and is known to reduce motor impairments and neuroinflammation in germ-free mouse models of PD resulting from α -synuclein. This persistent decline in populations of taxa that produce butyrate in the PD cohorts therefore suggests that reduced gut-derived butyrate is a mechanistic link to intestinal barrier dysfunction and neuroinflammation in PD [32]- [34].

2.5 Confirming Clinical and Metabolic Evidence

Supporting evidence from studies indicated that sigmoid colon biopsies of 38 PD patients compared to 34 controls had significantly higher levels of α -synuclein and significantly increased colonic mucosal permeability. In contrast, PD patients had significantly lower abundances of the bacteria that produce SCFAs (Firmicutes, Blautia, Coprococcus, and Roseburia). Specifically, these microbial alterations in the gut were not linked to levodopa medication or constipation, suggesting that they are not likely caused by the drug or PD symptoms—a finding that has cast doubt on the validity of numerous subsequent research. Not all subsequent cohorts have seen the decrease in Prevotellaceae. The enzymes needed to synthesize dopamine from dopa and to decarboxylate dopa into dopamine are produced in large part by Prevotella copri in the intestines. The vitamins B6, B1, and folate are also important components of this process. More than just a taxonomic relationship, the functional relevance of Prevotellaceae loss for dopamine bioavailability in PD implies a metabolic pathway of interest for disease pathogenesis [35].

2.6 Akkermansia muciniphila's role in health and disease

One of the most repeated, but counter intuitive, observations in the GBA-PD research field is the enrichment of Akkermansia muciniphila in PD patients. A. muciniphila is typically regarded as a beneficial, mucosal commensal bacterium of metabolic health and gut barrier integrity which is consistently elevated in PD within a variety of cohorts including European and North American patient populations [36]-[38].

The interpretation of the mechanism is still debated: the enrichment of A. muciniphila may be a secondary compensatory mechanism to compensate for gut barrier dysfunction, or the hypersecretion of mucolytic may have the opposite effect and increase LPS translocation and gut barrier dysfunction. A third interpretation – one that has not been confirmed – is that A. muciniphila affects dopaminergic signalling by its ability to produce propionate that can cross the blood–brain barrier and exert a complex neuroactive effect [39].

2.7 Shotgun Metagenomics and Functional Evidence

Most of the GBA-PD early studies have used 16S rRNA sequencing, but the shift to whole genome shotgun metagenomics has yielded significantly greater mechanistic insights. The first study using whole-metagenome shotgun sequencing (WMS) to investigate the PD gut microbiota in 31 PD patients and 28 healthy controls, using functional profiling with HUMAnN2.

They validated species-level changes in composition such as a reduction in the abundance of Prevotellaceae and an increase in the abundance of Enterobacteriaceae, while also revealing substantial functional differences at the species level, such as a decrease in SCFA biosynthesis pathways, a decrease in mucin degradation pathways, and an increase in LPS biosynthesis pathways, with the latter representing the first functional genomic evidence of linkage between gut microbiome alteration and inflammatory pathway dysregulation in PD [40].

More importantly, this study also revealed that antibiotic exposure history was a significant factor confounder for microbiome composition in PD cohorts, highlighting the critical importance of detailed medication recording in the design of studies.

2.8 Large-Scale Metagenomic Insights and Functional Variations

To date, the largest and most comprehensively phenotyped shotgun metagenomics study of the microbiome of PD microbiota sequenced 490 PD patients and 234 controls to a mean sequencing depth of 7.5 Gb per sample from the Parkinson's Foundation PD GENERation study and BioFIND biorepository. [41].

Using two tools, MetaPhlAn3 and HUMAnN3, they were able to identify 55 microbial species that had undergone significant changes. Among these changes were changes to functional pathways, such as a reduced pathway for indole-3-propionic acid, a decreased capacity to convert secondary bile acid, an increased capacity to produce lipopolysaccharide, and a decreased capacity for butyrate production (bacterial gene reduction). The pathophysiology of the microbiome can be better understood at a systems level with the help of network analysis, which revealed that PD is associated with changes in functionally coherent microbial modules rather than specific species. Additionally, this work demonstrated that microbiome variance was substantially impacted by PD drug use, constipation, and BMI, underscoring the necessity for stringent adjusters in GBA-PD trials [42].

2.9 Prodromal Microbiome Changes and Early Disease Signs

The question of whether dysbiosis of gut microbiome is a precursor to the onset of motor symptoms in PD is particularly exciting and clinically relevant, and may potentially allow for development of early biomarkers for the prodromal stage of the disease. There is a number of evidence to support this possibility [43].

Phosphorylated α -synuclein deposits have been found in the submucosal plexus in colonoscopic biopsy studies of people with idiopathic REM sleep behaviour disorder (iRBD), a prodromal PD syndrome with about 80% conversion to PD or related synucleinopathies over 10 years [44].

Dysbiosis of the iRBD cohorts has shown similarities with the dysbiosis previously observed in established PD, such as decrease in Prevotellaceae and reduction in Lachnospiraceae, suggesting a dysbiosis preceding motor symptom onset. The temporal relationship of constipation and PD further supports [45].

Role of Gastrointestinal Dysfunction in Early PD Pathogenesis

One of the earliest and most common prodromal symptoms of PD is constipation, which is a sign of ENS dysfunction and a decrease in gut motility, and is linked to a 2- to 4-fold higher risk of motor diagnosis of PD in prospective cohort studies.

Enteral transit time is a major determinant of the composition of the gut microbiome; in PD, a slow enteral transit may favour dysbiosis, through a mechanism of selection of saccharolytic and proteolytic fermenters, and of a loss of the competitive advantage of the butyrate-producing bacteria, which could trigger a vicious circle of dysbiosis, intestinal barrier dysfunction and consequent neuroinflammation before clinical disease [46].

3 Mechanistic Pathways: From Gut Dysbiosis to Dopaminergic Neurodegeneration.

3.1.1 α -Synuclein Misfolding and Prion-Like Propagation

The most direct mechanistic pathway proposed for the link between gut microbiome dysbiosis and PD neuropathology is the process of α -synuclein misfolding in enteric neurons that then spread to dorsal motor nucleus of the vagus nerve via retrograde flow along vagal efferent and afferent fibres and eventually to the brainstem, including the substantia nigra compelling experimental evidence that misfolded α -synuclein can be transferred from the gut to the brain through the vagus nerve, causing progressive dopaminergic neurodegeneration with a temporal progression similar to that observed in PD.

The big question in the research of GBA-PD remains: Can gut microbiome dysbiosis lead to the initiation or progression of α -synuclein misfolding?

There are a number of suggested mechanisms. Structural homology exists between bacterial amyloid proteins, such as curli fibres of *E. coli* and other Enterobacteriaceae, which are enriched in PD, and α -synuclein, and they have been demonstrated to induce cross-seeding of α -synuclein aggregation [47].

3.1.2 Experimental Evidences from Animal Models

The gut microbiota play a crucial role in the full manifestation of motor impairments and neuroinflammation in transgenic mice that express α -synuclein through the *Thy1* gene (*Thy1-SNCA*), according to a revolutionary study. The researchers found that GF mice exhibited far lower levels of α -synuclein aggregation, microglial activation, and motor impairments as contrasted with controls that had conventional colonization. This is the first experimental evidence linking dysbiosis associated with Parkinson's disease to motor neurodegeneration; microbiota from PD patients considerably reduced motor function in GF mice compared to healthy controls. Furthermore, the GF mice who were given SCFA as a supplement showed signs of microglial activation and α -synuclein pathology, which might be explained by specific microbial metabolites acting as intermediaries. [48]

3.1.3 Dysfunction of Gut Barrier and Systemic Inflammation

The dysfunction of the gut barrier (GB) and the associated increased permeability, which results from dysbiosis-mediated disruption of tight barrier proteins such as occludin, claudin-1 and ZO-1, is a consequence and is likely to be a perpetuating cause of GBA dysregulation in PD. Raised

serum levels of markers of intestinal permeability (zonulin, fatty acid binding protein-2, LPS-binding protein) have been found in PD patients and are correlated with disease duration and burden of non-motor symptoms, respectively [49].

3.1.4 Neuroinflammation and Selective Dopaminergic Neuron Vulnerability

LPS and flagellin are translocated across a leaky epithelial barrier to activate lamina propria dendritic cells and macrophages by triggering TLR4 and TLR5 activation, pro-inflammatory cytokine release (TNF- α , IL-1 β , IL-6, IL-17), and activation of the NLRP3 inflammasome [50]. LPS reaches the CNS through several mechanisms: pro-inflammatory cytokines disrupt the integrity of the blood brain barrier (BBB), they act on circumventricular organs that lack a complete BBB; activated monocytes and T lymphocytes transmigrate into the CNS parenchyma [51]. In the brain, LPS-priming of microglia is a particular vulnerability and chronic activation of these cells in PD creates a neuro-inflammatory milieu of reactive oxygen species, pro-inflammatory eicosanoids and glutamate excitotoxicity which drives the death of dopaminergic neurons [52]. Why substantia nigra dopaminergic neurons are more vulnerable to this inflammatory cascade, as compared to, for instance, cortical neurons, may have to do with their relative lack of antioxidant capacity, high basal metabolic rate, and comparatively low levels of trophic support [53].

3.1.5 Short-Chain Fatty Acids as Neuromodulators

Microbiologically derived SCFAs (especially acetate, propionate and butyrate) are an important mechanistic connection between gut microbiome composition and CNS function in PD. Butyrate is the main source of energy to the colonocytes and has several neuroprotective effects: it inhibits histone deacetylases, increasing the expression of neurotrophic factors such as BDNF and GDNF [54].

It triggers the release of the neuroprotective peptides YY (PYY) and glucagon-like peptide-1 (GLP-1) by activating the GPR41 and GPR43 on enteroendocrine cells [55].

Through GPR109a signaling, it inhibits microglial activation, and it modulates gene expression in neurons and astrocytes by directly crossing the blood-brain barrier [56].

Evidence from both metabolomic (faecal SCFA concentrations measured by gas chromatography-mass spectrometry, or GC-MS) and metagenomics (shotgun metagenomics functional profiling) approaches is consistent with lower concentrations of SCFA in the faeces of PD patients, particularly butyrate and propionate, and with decreased expression of butyrate-producing genes in the gut microbiome of PD patients. *Bacteroides* spp., *Veillonella* spp., and *Akkermansia* spp. all have complicated neuroactive qualities that are dose dependent, and propionate is mostly produced via the succinate and acrylate routes. At physiological doses, propionate has anti-inflammatory, intestinal gluconeogenesis-regulating, and free fatty acid receptor (FFAR3/GPR41) activating effects [57].

When administered intraventricularly, propionate produces neuroinflammation and movement abnormalities in rats, as well as the social and behavioral deficits associated with autism and mitochondrial dysfunction at supraphysiological doses in rats. Future study within GBA-PD

should focus on determining the overall impact on PD when adding Akkermansia changes propionate signaling (e.g., more propionate accessible in the colon) [58].

3.1.6 Tryptophan metabolism and the Kynurenine pathway

Tryptophan is an essential amino acid that is absorbed from the diet in the small intestine and is the precursor of serotonin, melatonin, and the metabolites of the Kynurenine pathway, and the metabolism of all these compounds is significantly affected by gut microbiota. The enzymes indoleamine 2,3-dioxygenase (IDO1, IDO2) and tryptophan 2,3-dioxygenase (TDO) convert about 95% of dietary tryptophan into kynurenine, which can then be converted to neuroprotective kynurenic acid (via kynurenine aminotransferases) or into neurotoxic quinolinic acid (via 3-hydroxykynurenine and kynurenine 3-monooxygenase).

In PD, gut microbiome dysbiosis switches tryptophan catabolism towards the quinolinic acid branch of the Kynurenine pathway, leading to a decrease in the serum and CSF Kynulinic acid/Quinolinic Acid ratio in PD patients, and Quinolinic acid has been shown to activate NMDA receptors and to induce excitotoxic dopaminergic neurodegeneration. The cohort further supported this with direct genomic evidence of reduced microbial pathway capacity to produce indole-3-propionic acid (IPA), a neuroprotective tryptophan catabolite produced specifically by gut microbes, suggesting microbial pathway dysbiosis in PD is causing a perturbation of neuroprotective tryptophan metabolism [59].

The relationship between genetic factors and gut microbiome in PD

Mutations and copy number variations of the SNCA (α -synuclein), LRRK2 (leucine-rich repeat kinase 2), GBA1 (glucocerebrosidase), PINK1, and Parkin genes explain about 10-15% of PD cases, with LRRK2 G2019S being the most prevalent pathogenic variant in European populations [60].

This has generated a promising avenue of research on the interactions between genes and the microbiome in PD. LRRK2 is highly expressed in intestinal macrophages and Paneth cells, and plays a role in the regulation of innate immune signalling and autophagy pathways related to microbial surveillance [61].

LRRK2 G2019S mutation carriers with and without PD exhibit similar gut microbiome alterations (both Prevotellaceae depletion and Lachnospiraceae reduction) than non-carriers, indicating that LRRK2-induced alterations in gut immune function may affect the dysbiosis underlying the onset and/or progression of PD pathogenesis, independent of motor symptom onset [62].

On a molecular level, the ability of LRRK2 mutations to modulate inflammatory responses to microbial LPS by controlling MAPK signalling pathways offers a plausible molecular link between genetic susceptibility and gut-microbiome-mediated neuroinflammation. The most frequent genetic risk factor for PD is a mutation in the GBA1 gene which codes for glucocerebrosidase, the enzyme that is lacking in Gaucher's disease, with a frequency of 5–15% of PD patients, depending on the ancestry. Glucocerebrosidase activity in the gut is involved in glycosphingolipid metabolism in colonocytes and immune cells, and variant carriers have a different composition of their faecal microbiome to non-carriers it is not known whether this is

the direct result of the mutation on gut epithelial biology or the consequence of a primary PD effect, as the gut microbiome is shaped by many factors. GBA1 status is an important confounder that needs to be stratified in large-scale GBA-PD metagenomic studies [63].

Targeting Microbiome Therapy with Mechanistic Basis

The methods used to treat gut microbiota are based on several biological processes: first, the fermentation of dietary fiber in the small intestine produces SCFAs like acetate, propionate, and butyrate, which regulate neuroinflammation and vagus nerve function; second, gut-derived bacteria produce neurotransmitters like serotonin, gamma-aminobutyric acid (GABA), and dopamine precursors, which modify neural signaling [65].

Role of SCFAs and Psychobiotics in Brain Function

SCF Also, by boosting the signaling pathways linked to synaptic flexibility and neuronal survival, they enhance neurogenesis and the integrity of the blood-brain barrier. The prospective therapy impact of microbiome manipulation is the increased expression of neurotrophic factor derived (BDNF), which is triggered by microbiome interventions, according to experimental findings. Psychobiotics are a family of agents that activate the gut-brain axis and promote mental health. They can be probiotics, postbiotics, prebiotics, or synbiotics. Psychobiotics have a psychotropic effect on stress, anxiety, and depression. The neuroendocrine system, immunoregulatory mechanisms, and vagus nerves all stimulate interactions between gut and brain microbes [66].

Psychobiotics can affect the brain's neurotransmitters and proteins, the HPA axis, or of inflammatory chemicals directly associated with depression, or the intellectual and emotional pathways.

Microbial Therapeutics and Future Prospective in Neurodegenerative Diseases

Human flora such as *Lactobacillus* GG and *Bifidobacterium infantis* 35, 624 stimulate interleukin-10, which in turn decreases pro-inflammatory cytokines and either directly or indirectly maintains the integrity of the blood-brain barrier. Acetylcholine is synthesized by strains of *Lactobacillus* *Lactobacillus* *odontolyticus* and *Lactiplantibacillus* *plantarum*. In humans, spore-forming gut microorganisms also cause the enterochromaffin cells to produce more serotonin. When utilized to treat a variety of mental illnesses, such as Parkinson's disease, Alzheimer's disease, Tourette syndrome, autism, and insomnia, psychobiotics—and FMT in particular—have shown positive outcomes. FMT has been shown to be successful in treating symptoms of depression and anxiety.

Human microbes like *Lactobacillus* GG and *Bifidobacterium infantis* 35, 624 augment the interleukin-10 and consequently by trimming down pro-inflammatory cytokines either directly or indirectly help preserve the integrity of the blood-brain obstacle. *Lactobacillus* *Lactobacillus* *odontolyticus* and *Lactiplantibacillus* *plantarum* are strains that produce acetylcholine. There is also a similar increase of serotonin production by the enterochromaffin cells by spore-forming gut microbes in humans. Psychobiotics, and primarily, FMT have recorded positive effects when used in management of numerous mental conditions including but not limited to Parkinson

disease, Alzheimer disease, Tourette syndrome, autism, and insomnia. FMT was established to be effective in alleviating the state of depression and anxiety. Therefore, psychobiotics have come as a remedy to all sorts of neurodegenerative disorders. It may be a valuable and promising approach towards healthy well-being. Human studies have not yet been done despite promising results. Additional studies in the field of psychobiotics should be carried out to use it as an alternative treatment in neurodevelopmental and neurodegenerative diseases. [67]

PROBIOTICS

The ability of probiotics, which are live microorganisms to improve health benefits to the host, has been a focus of research in relation to the microbiome-gut-brain axis. Psychobiotics, originally defined as probiotics with health benefits to the host achieved through gut-brain interactions, has mood-enhancing effects, reductions in anxiety and depression scores, and improvements in stress reactions. This definition has been broadened to encompass other ways to target the microbiome that could potentially improve brain process. Certain strains of bacteria have also been shown to reduce inflammation in preclinical models, including an inflammation model caused by a high-fat diet, where *Lactobacillus* and *Enterococcus* strains were able to reduce IL-6, TNF- α and IL-1 β , but not anxiety [68].

Strain-Specific Effects and Neurobehavioral Outcomes

Strain specificity is of great importance; in an example, *B. longum* was able to reduce depression in individuals with irritable bowel syndrome (IBS), but not anxiety in another study. *plantarum* also reduced stress. Certain probiotics (e.g. *Bifidobacteria* and *Lactobacilli*) have demonstrated potential to improve behavioral and neurochemical impairments in preclinical models of ASD, with *Bifidobacteria* and *Lactobacilli* enriching behavioral and neurochemical impairments; but no significant changes in TNF- α , IL-6, and IL-1 β or cortisol were found in any group of probiotics tested in a single study [69].

Psychobiotics and Immune Modulation

Schizophrenia has been linked with peripheral immune abnormalities, although probiotics have not demonstrated much psychiatric effect. The reduction in von Willebrand factor and the modulation of monocyte chemoattractant protein-1, brain-derived neurotrophic (BDNF), chemokine ligand 5, and macrophage inflammatory protein-1 β . Pathway analysis indicated that the inhibition of the changes in *L. rhamnosus* and *Bifidobacterium animalis* supplementation is associated with the decrease of IL-17 cytokines in the regulation of immune and intestinal epithelial cells, as well as involved changes in monocytes. Positive outcomes on anxiety and depression in schizophrenia and elevation of TNF-related activation-induced cytokine and IL-22 in respondents are also observed in open-label studies involving *Bifidobacterium breve*, but lacking placebo arm [70].

PREBIOTICS

Prebiotics are an alternate strategy for influencing the microbiome-gut-brain axis. These are indigestible substances that have been hand-picked to influence host microbes in a way that favours good microbes. Fruits, vegetables, entire grains, and even human milk contain prebiotics. Many other foods also include these beneficial bacteria. The proliferation of beneficial

microorganisms like *Bifidobacterium* is one way in which prebiotics may enhance gut health and, by extension, brain health [71].

For example, a review article indicated that healthy individuals can reduce the cortisol awakening response after three weeks of high-dose GOS supplementation, and prebiotics like FOS and GOS have changed the makeup of gut microbes and reduced stress reactions [72]. This suggests that prebiotics may play a role in regulating gut and mental health. Furthermore, prebiotics have the ability to influence in utero VPA-induced alterations in an autism spectrum disorder (ASD) mouse model by lowering levels of specific microbes, increasing intestinal permeability, reestablishing immunological homeostasis, decreasing neuroinflammation (namely, CD68 expression), and improving social behavior and cognition in children exposed to VPA during gestation [73].

Prebiotics also changed levels of corticosterone and BDNF expression in the hippocampus, two important neurobiological pathways associated with neuropsychiatric disorders. To fully understand the therapeutic potential of prebiotics, however, further research in humans is required to determine how these microbes affect mental health.

FMT (Fecal microbiota transplantation)

FMT is conducted by the application of the therapeutic population of the microbes. FMT is an attractive technique to substitute the pathogenic microbes with the healthy microbes. It entails relocation of healthy microorganisms to the recipient of healthy donors using different delivery methods. The donor should be screened on stringent guidelines. To ensure that the donor infects the recipient, it is required that appropriate stool and blood tests be conducted within 4 weeks prior to transplantation. To induce immunotolerance by the recipient to the microbes of the donor, it is preferable that a close relative of recipient is used as the donor and not an unrelated donor in the event of a genetic disease like inflammatory bowel disease. [74].

Clinical Significance and Therapeutic Benefits of FMT

It was discovered that fecal filtrate with bacterial debris, metabolites, DNA etc. was simply sufficient to treat recurrent *Clostridioides difficile* infection (CDI). Recurrent CDI was treated with pure culture of intestinal bacteria of one healthy donor only. FMT has been effectively employed in the treatment of antibiotic caused dysbiosis in *C. difficile* infection. FMT has also been effectively applied in treating recurrent *C. difficile* infections with a breathtaking percentage of recovery (with the percentage of success significantly lower than those of CDI). The fecal microbes of the lean mice had to be transferred to the obese mice to restore the butyrate producing bacteria and enhance the production of insulin. Post FMT, the prevalence of antibiotic-resistant pathogens linked to infections of the urinary-tract were radically decreased. Some diseases like alcoholic hepatitis and cirrhosis are linked with the lack of the mucosa-associated invariant T-cells. FTM has been found to restore these T-cells in patients. Likewise, the loss of *Bacteroidetes* caused by alcohol was recreated following FMT. Successful efficacy Experts related to FMT have carried out a number of clinical trials in the case of liver disorders, evolution of fibrosis, hepatic encephalopathy and alcoholic hepatitis. FMT has been effectively researched in some neurological disorders like autism, sclerosis and Parkinson disease. The fecal microbes transfer of healthy to cancer patients enhanced the response to the immune checkpoint inhibitors [75].

Limitations, Risks, and Future Directions of FMT

Determined by the host genes linked to the immune system, the efficacy of the FMT process depends on the heritability of the transferred microorganisms. Research has shown that FMT can effectively treat ulcerative colitis and increase the likelihood of remission. Similarly, FMT treatment was ineffective in cases of chronic Crohn's disease. When β -lactam-resistant *Escherichia coli* is transferred, immunocompromised persons may suffer from the negative consequences of fecal transmission. In response to the adverse effects of FMT and the health risks associated with foul stools, a new approach to FMT was developed: artificial stool. This method involves fermenting and formulating feces commensals in a controlled environment that mimics the human gut, and then packaging them in a living form. It is also possible to restore the native gut microorganisms by replacing the patient's stool in cases of severe infections [76].

Table 2 : Functional Roles of Key Gut bacteria in Parkinson Disease Pathogenesis

Taxon	GBA relevance
<i>Faecalibacterium prausnitzii</i>	Butyrate production → anti-inflammatory, gut barrier integrity
<i>Akkermansia muciniphila</i>	Mucin degradation, gut permeability regulation
<i>Lactobacillus</i> spp.	GABA production, vagal signalling, tryptophan metabolism
<i>Bifidobacterium</i> spp.	GABA, acetate, SCFA; immune modulation
<i>Prevotella copri</i>	Propionate production; possible neuroinflammation link
<i>Ruminococcus</i> spp.	Butyrate, cross-feeds other SCFA producers
<i>Enterobacteriaceae</i>	LPS production → systemic inflammation → neuroinflammation

3.METHADOLOGIES

The methodology for Shotgun Metagenomics of the Gut Microbiome

The gut microbiome has been described using whole-genome shotgun (WGS) metagenomics, which is the most comprehensive method currently available, and is becoming the gold standard method for mechanistic studies of the gut-brain axis (GBA). In contrast to 16S rRNA amplicon sequencing which can only be used to provide taxonomic profiles at genus level, and lacks direct functional information, shotgun metagenomics randomly fragments and sequences all DNA in a biological sample, including both bacterial, archaeal, viral, fungal and residual host genomes. This method provides a genome-wide, unbiased snapshot of the whole microbial community, allowing species- and strain-level classification, construction of functional gene catalogues, quantification of metabolic pathways and recovery of metagenome-assembled genome (MAG) and profiling of antibiotic resistance genes in a single experimental workflow. For GBA research modelling, where the mechanistic questions focus on the identities of organisms producing

neuroactive metabolites (e.g., γ -aminobutyric acid (GABA), short-chain fatty acids (SCFAs) and tryptophan catabolites), and by what biosynthetic route, the functional resolution enabled by the shotgun metagenomics approach is scientifically essential [64].

3.1 Sample Collection and Preservation

Step 1: Faecal Sample Collection

The faecal samples should be collected using validated nucleic acid stabilisation systems, e.g. OMNIgene•GUT OM-200 tube (DNA Genotek). Otherwise immediately freeze in liquid nitrogen [77].

Step 2: Sample Storage Samples

Sample Storage Samples must be stored at -80°C for long term storage within 15 minutes of voiding. At room temperature, the composition of the gut microbial community changes significantly over a period of 2–4 hours.

After one freeze-thaw (FT), microbial composition is significantly changed [78].

Step 3 : Use of OMNIgene•GUT System

DNA was stable over 60 days at ambient temperature with the OMNIgene•GUT system and with no measurable distortion of the DNA's composition. This system provides logistical benefits for large multi-site cohort studies while maintaining study analytic integrity [79].

Step 4: Coordinated Multi-Sample Collection

When matched collection at the same timepoint should contain:

1. Peripheral blood serum
2. Urine
3. Saliva

Step 5: Blood Serum Analysis Serum

It is taken from the peripheral blood for:

- Systemic metabolomics
- Inflammatory cytokine
- profiling: $\text{TNF-}\alpha$
- IL-6
- IL- 1β

CRP by multiplex ELISA

Gut permeability markers:

Zonulin , fatty acid binding protein-2. LPS-binding protein

Step 6 : Urine and Saliva Collection:

At the same time the patient's urine and saliva samples are collected. Untargeted metabolomics is done using urine. Oral microbiome characterisation: collection of saliva. These analyses allow for multi-omic analysis of gut-brain communication pathways to be integrated [80].

Step 7: Metadata Recording

The following are important points that comprehensive metadata should include: Exposure to antibiotics in the six months before testing.

All medications including prescriptions and over-the-counter, particularly:

- Proton pump inhibitors , Metformin , SSRIs , Antipsychotics , Laxatives

Dietary patterns judged by:

- Validated 24-hour recall
 - i. Food frequency questionnaire
 - ii. Bowel habit regularity – quantified using Bristol Stool Scale.
 - iii. Body mass index.
 - iv. Smoking and drinking.

Psychiatric assessment scores that comprised of:

3. The patient Health Questionnaire-9 (PHQ-9)
4. Generalised Anxiety Disorder-7 (GAD-7)

3.3 DNA Extraction

Step 1: The first step is the selection of the method of DNA extraction.

The first step is choosing the method for extracting the DNA. The DNA extraction is recommended to be performed using the Qiagen PowerSoil Pro Kit. Shotgun metagenomics is dependent on high quality and high quantity of DNA since each step of the library preparation and quality of the DNA sequencing and subsequent analysis by assembly is sensitive to DNA fragmentation, purity and quantity [81].

Step 2: Enzymatic Pre-Lysis

An enzymatic pre-lysis is done with: Lysozyme (10 mg/mL) Mutanolysin (250 U/mL) Samples are cultured for 1 hour at 37 °C.

This partially digests the gram-positive bacterial cell walls before disrupting them mechanically.

Step 3: Mechanical Disruption Bead beating

It is done at a speed of 6.0m/s for 40s. A combination of: Garnet beads 0.1 mm glass beads This is using an MP Biomedicals FastPrep-24 5G instrument.

Step 4: A gram-positive bacterial lysis occurs

The enzymatic-mechanical method is more effective than bead-beating alone in reaching a much higher degree of lysis of Firmicutes. This will minimize the systematic under-representation of gut-brain axis gram-positive taxa.

Step 5 : Assessment of DNA purity

Spectrophotometrically, the purity of DNA is determined.

Target values: OD_{260/280} ratio: 1.8–2.0 , OD_{260/230} ratio: >1.7 Deviations indicate residual: Protein , Polysaccharide and Humic acid contamination.

Step 6: DNA Quantification

To measure the quantity of DNA, the following is used:

Qubit 4 Fluorometer

dsDNA Broad Range Assay Kit (Thermo Fisher Scientific)

Target yield: 500 nanograms to 5 micrograms

Step 7: DNA Integrity Analysis

The integrity of DNA is checked by: Agilent TapeStation Genomic DNA ScreenTape analysis.

Acceptable quality: DNA Integrity Number (DIN) ≥ 7 Strong band at frequencies of more than 20 Kb.”

Step 8 Quality Control Procedures

There are two procedural controls in each extraction batch:

Extraction Blanks uses only processing chemicals and not biological material.

Used for background contamination for kit associated ("kitome").

ZymoBIOMICS Microbial Community Standard D6300 Mock community containing:

Eight bacterial species and Two fungal species

Used to monitor: Extraction efficiency, Lysis completeness and Inter-batch reproducibility.

Step 9 : The host DNA is depleted

For GBA samples containing high amount of human DNA: MolYsis Complete5 kit Saponin-based differential lysis Applied before being mined. Microbial reads are 3- to 10-fold higher with host depletion and sequencing cost is a fraction of what it is without host depletion.

DNA Fragmentation and Library Preparation

Our first step is to break apart the genome in order to prepare a library. The first step is to fragment the DNA and prepare a library. The workflow to prepare libraries transforms high molecular weight genomic DNA into short, uniformly sized, sequencer compatible, adapter and index sequence tagged DNA molecules. Acoustic fragmentation is recommended via the Covaris E220 Focused-ultrasonicator at 350 watts peak power, 5% duty factor, 200 cycles per burst and a treatment time of 60 to 80 seconds for Illumina 2×150 base pair paired-end chemistry products with a median insert size of 200-350 base pairs

Unlike enzymatic alternatives to shearing like Nextera XT tagmentation, which have a known insertion sequence bias and preferentially fragment accessible chromatin regions in the genome, Covaris acoustic shearing generates a consistent and highly reproducible size distribution with no insertion sequence bias across the genome. Size selection after fragmentation by removing DNA fragments < 100 bp (which yield non-informative adapter-dimer reads) and residual genomic DNA > ~800 bp (which would adversely affect bridge amplification clustering efficiency for Illumina sequencing) is achieved by using the AMPure XP paramagnetic bead purification system at the 0.6 vol : vol ratio.

The size distribution is checked by Agilent Bioanalyzer DNA 1000 chip or TapeStation D1000 ScreenTape, which shows a tight peak at the targeted insert size with the added 130 base pairs

from the ligated adapters. Both end repair and dA-tailing are done with the NEBNext Ultra II FS DNA Library Prep Kit (New England Biolabs) using T4 DNA polymerase for blunt end generation and Klenow fragment exonuclease for 3'-dA overhang addition.

Illumina sequencing adapters containing unique dual indexes (UDIs), are ligated with T4 DNA Ligase at 20°C for 15 minutes and then the hairpin loop structure in the adapter is cut by USER enzyme. For multiplexed NovaSeq sequencing using patterned flow cells, the use of unique dual indexes (rather than combinatorial dual indexes) is required, and index hopping rates of 0.1–1% have been reported, which could result in non-trivial levels of cross-sample contamination in cases where many GBA-relevant taxa are detected at sub-0.1% relative abundance.

Library preparation is done using 8–12 cycles of PCR amplification with KAPA HiFi HotStart ReadyMix (Roche) to minimise GC-content amplification bias and chimera formation; if sufficient input DNA ($\geq 1 \mu\text{g}$) is available, PCR-free library preparation (Illumina TruSeq PCR-Free or KAPA HyperPrep PCR-free) is strongly recommended to eliminate amplification bias completely and to improve coverage uniformity across high-GC genomic regions that are over-represented in Actinobacteria, such as the GBA-relevant *Bifidobacterium* species.

Final library quantification is performed using both Qubit dsDNA High Sensitivity fluorometry and quantitative PCR using an Illumina-compatible library quantification standard (KAPA Library Quantification Kit) and individually quantified libraries are further normalised to a 4 nM working concentration, pooled equimolarly across the sample cohort, denatured to 20 pM, and supplemented with a 1% PhiX control library spike-in to provide increased nucleotide diversity during Illumina base-calling.

Sequencing Platform and Depth

The platform is the surface on which the ball is placed. Platform is the area the ball rests on. Current platforms for large-scale gut metagenomic studies are the Illumina NovaSeq 6000 or NovaSeq X Plus, which uses patterned flow cells and either 2×150 or 2×250 base pair paired end sequencing, and provide between 300 gigabases and 6 terabases per run at around £150 – 400 per sample, depending on sequencing depth and batch size.

To ensure reliable metabolic pathway reconstruction using HUMAnN3, a minimum sequencing depth of 10 gigabases per sample (around 50 million paired-end read pairs) is required; less than about 5 million reads mapped to coverage of metabolic pathways of low abundance microbial contributors to the GBA-relevant metabolic routes is not reliable.

Sequencing depths of 20–30 gigabases per sample are sufficient to get the contig depth coverage ($>10 \times$ median coverage) needed for reliable assembly and binning for studies focused on MAG recovery and novel species characterisation. Shallow shotgun metagenomics, meaning sequencing at a depth of 1–2 gigabases per sample, has been shown to be a cost-effective method for species-level taxonomic profiling and coarse functional classification, and has proven to be effective in several large GBA cohort studies.

Long-read sequencing platforms, like those of Oxford Nanopore Technologies (PromethION) with ultra-long reads (50-100 gigabases per flow cell) and accuracy over 99.9%, and PacBio

(Revio), 15-20 kilobase HiFi reads, are also shown to provide complementary data to support strain-level resolution, near-complete MAG assembly, and detection of structural variants.

For new species characterization from GBA cohorts, hybrid assembly approaches that leverage the strengths of both long and short read data are the current best practices for metagenomic studies.

Bioinformatic Processing: Quality Control and Host Decontamination

Prior to any analysis of the sequences, a standardised quality control and host decontamination pipeline is applied to the raw sequencing reads. Quality assessment is carried out using FastQC and multi-sample reports using MultiQC and requiring a minimum of 80% of bases at Phred quality score Q30 or higher, acceptable per-base quality scores across the length of the reads, consistent distribution of GC content with respect to the expected microbial community, and low levels of adapter contamination, less than 1% of reads. Adapter trimming and quality filtering are performed using fastp with the following parameters: per-base quality score minimum, Q20; minimum length of the read after adapter trimming, 50 bp; automatic detection and removal of paired-end adapters. All human faecal metagenomic samples must undergo host read decontamination prior to taxonomic and/or functional analysis. The reads are quality filtered and aligned against the human reference genome GRCh38 with Bowtie2 with sensitive-local alignment parameters, all concordantly and discordantly mapping read pairs are removed and the unmapped read pairs are retained as the microbial fraction for downstream processing. The high proportion of reads that map to the human genome typically ranges from 10 to 50%, and can be significantly higher for faecal samples that contain mucosal epithelial cells, blood or inflammatory exudate, as might be found in GBA studies of patients with intestinal barrier dysfunction, inflammatory bowel disease, or colonic biopsies. Post-decontamination samples with fewer than 5 million microbial read pairs are marked and either not used for pathway-level analysis or only used for shallow-shotgun taxonomic analysis because the number of reads at this level is not sufficiently deep to support power-ful pathway reconstruction.

Taxonomic Profiling

Host-depleted metagenomic reads are taxonomically profiled at the species level and subspecies level using MetaPhlAn4 which uses around 5.1 million clade-specific marker genes from 99,000 reference genomes and high-quality metagenome-assembled genomes to obtain relative abundance profiles with a very low false-positive rate through taxonomic profiling. To complement and cross validate, a complementary and less sensitive approach to Kraken2 is applied with the Bracken abundance estimation method using the reference database PlusPF, which includes all RefSeq bacterial, archaeal, viral, fungal, and protozoan sequences from NCBI. Taxonomy assignments from both tools are cross checked and merged to achieve the highest possible level of sensitivity and specificity in the final abundance table.

Functional Profiling

Functional pathway analysis is carried out with HUMAnN3, a three steps computationally efficient functional pathway annotation approach. In the first tier, species profiles are identified by MetaPhlAn4 and used to select species-specific sequence databases from the ChocoPhlAn

v296 database that are then aligned to reads using Bowtie2 to calculate per-gene-family read counts. In the second tier, then the reads that are not detected by the first tier are searched for translated sequences against the UniRef90 protein sequence database using DIAMOND to retrieve functional signal from genes in poorly characterised or undetected organisms. Normalisation is based on read counts per gene (RPK), and then gene families are aggregated into the abundance of metabolic pathway using MinPath for both MetaCyc and KEGG pathway databases (copies per million sequenced reads). The functional outputs of particular interest for GBA research are the pathways for GABA biosynthesis (MetaCyc PWY-5022), the pathways for biosynthesis of tryptophan and catabolism of kynurenine (MetaCyc TRPSYN-PWY, KYNURENINE-PWY), pathways for synthesis of SCFA including butyrate (BUTANESYN-PWY), propionate (P108-PWY), and conversion to acetate, enzyme families for DOPA decarboxylase enzyme functions relevant to microbial biosynthesis of dopamine precursors, and the capacity to synthesize LPS as a proxy for systemic inflammatory potential.

Strain-Level Analysis

Strain-level resolution below the species level is enabled by SNP based-profiling of per-sample consensus sequences that can be reconstructed at the clade-specific positions of marker genes defined by the MetaPhlAn4 algorithm, distributed in bioBakery3 suite, and by multi-sample phylogenetic analysis of these sequences, to detect strain-level population structure and transmission events. This strain-level resolution is completely unachievable through 16S sequencing, and needed when looking at the functional properties of probiotic versus commensally co-occurring strains, as in the case of *Lactobacillus rhamnosus* JB-1, which is known to produce GABA and have anxiety-attenuating effects, versus other *L. rhamnosus* strains without the same properties (Bravo et al., 2011). inStrain (Olm et al., 2021) offers complementary within-sample and between-sample average nucleotide identity and nucleotide diversity calculations, which can be used to monitor strain colonisation patterns, micro-evolutionary changes and transmission chains over the time points of a longitudinal GBA intervention study.

The metagenome assembly and MAG recovery step. The metagenome assembly and MAG recovery step is step 3.10. Host depleted reads are assembled de novo using MEGAHIT for single assembly or metaSPAdes for complex microbial communities for assembly purposes that are computationally efficient and suitable for studies that aim to characterise new uncultured species of microbes with putative GBA-relevant properties. Contigs are assembled and binned into MAGs using an ensemble of three assemblers (MetaBAT2, CONCOCT and MaxBin2) and the best non-redundant set of bins is selected by DAS_Tool. MAG quality is evaluated with CheckM2 and high quality MAGs are those with $\geq 90\%$ completeness and $\leq 5\%$ contamination according to MIMAG guidelines. GTDB-Tk is used to classify taxa and eggNOG-mapper to annotate functions based on eggNOG 5.0 database, including screening for gene families relevant to GBA: glutamate decarboxylase (gadA/gadB for GABA synthesis), butyryl-CoA transferase (but), tryptophan synthase (trpAB), and tyrosine decarboxylase (tdc).

Statistical Analysis

The abundance differences of each clinical group compared to the other groups are analyzed using ANCOM-BC2, an explicit model and correction for compositional nature of metagenomic

count data and total variation of microbial biomass in different samples, resulting in unbiased estimation of log fold-change with false discovery rate correction by Benjamini-Hochberg procedure. Multivariable analyses involving GBA-relevant confounders such as psychiatric diagnosis, drug exposure, dietary patterns, bowel transit time, and demographic variables use an implementation of the LASSO-regularised variable selection method for fitting GLMs to identify microbial features that are independently associated with GBA phenotypes of interest. Alpha diversity indexes (Shannon entropy, observed species, Faith's Phylogenetic Diversity) are compared between groups either by Kruskal-Wallis test with Dunn post hoc test, or by linear mixed models for longitudinal data; beta diversity (Bray-Curtis dissimilarity and Aitchison distance) is analysed by PERMANOVA with 999 permutations and with homogeneity of dispersions verified by PERMDISP2. Within the mixOmics framework, DIABLO is used to integrate metagenomic pathway data with metabolomics, host transcriptomics and clinical neuroimaging data, using sparse partial least squares discriminant analysis to identify correlated cross-omic signatures that are linked to GBA phenotypic outcomes.

Omics Category	Tool Name	Function	Application
Biomarker Profiling	Random Forest (ML-based)	Microbiota composition	Biomarker discovery & classification
Metagenomics	QIIME 2	Microbiota functional gene capacity	16S rRNA & shotgun data analysis
Metabolomics	XCMS	Metabolic productivity	LC-MS data processing
Metatranscriptomics	HUMAnN3	Microbial functional gene Expression	Functional activity profiling
Metaproteomics	MaxQuant	Protein Expression	Protein identification & quantification

Table 2 : Integrated multi-omics platforms and representative bioinformatics tools employed for comprehensive analysis of microbial communities.

Omics Category	Tool Name	Function	Application
Biomarker Profiling	Random Forest (ML-based)	Microbiota composition	Biomarker discovery & classification
Metagenomics	QIIME 2	Microbiota functional gene capacity	16S rRNA & shotgun data analysis
Metabolomics	XCMS	Metabolic productivity	LC-MS data processing
Metatranscriptomics	HUMAnN3	Microbial functional gene Expression	Functional activity profiling
Metaproteomics	MaxQuant	Protein Expression	Protein identification & quantification

16S rRNA Gene Sequencing

Step 1: Collect the sample. Gut, skin, soil — where microbes reside.

Step 2: Extract DNA Lyse cells to release all microbial DNA The 16S rRNA gene was amplified

Step 3: Involved amplifying the 16S rRNA gene. Copy a "barcode" gene that is present in in ALL bacteria — NOT in human cells The 16S gene Has 9 "variable" regions (V1–V9). Like a fingerprint for each species.

Step 4: Sequence the DNA Read the A, T, G, C letters in the gene.

Step 5: Match to a database Compare sequences to other known sequences; find similarities and differences Please provide an identifier for your sequences, such as SILVA or Greengenes database.

Step 6: Bioinformatics analysis Cluster into OTUs/ASVs, and count the number of species
Objective: Who are the people that inhabit this area? Which bacteria, how many and in what way do they enter the system? what proportion.

Procedure

1. **Collect** — swab, stool, soil or water sample that has microbes in it.

2. **Extract DNA** — the cells are broken open chemically, all of the DNA from each microbe is extracted simultaneously.
3. **Amplify (PCR)** – primers bind to the conserved flanking regions, scientists make millions of copies of only the 16S gene from each organism present.
4. **Sequence** – modern machines read the DNA letter by letter (Next-Generation Sequencing can read millions of letters at once).
5. **Match to database** — each sequence is compared to reference databases. If it is 97%+ identical to a recognized bacterium, then it is labelled in that way.
6. **Analyze** – sequences are grouped into OTUs (Operational Taxonomic Units) or ASVs (Amplicon Sequence Variants) which are essentially groups of organisms. They are counted and compared using software.
7. **Results:** Your picture of your microbial community is revealed: What bacteria are present, how abundant and how diverse?

4. RESULT

The thorough review of published literature revealed a consistent and reproducible change in the gut microbiome of Parkinson disease (PD) patients. In both cross-sectional and metagenomic studies, there was a marked decrease in the levels of short-chain fatty acid (SCFA)-producing bacteria, such as *Faecalibacterium prausnitzii*, *Roseburia intestinalis*, and members of the Lachnospiraceae and Ruminococcaceae families. Simultaneously, a greater number of Gram-negative bacteria, such as Enterobacteriaceae and Akkermansia muciniphila, was found to be pro-inflammatory, consistently. These microbial changes were highly correlated with functional changes, such as reduction in the production of short-chain fatty acids, increase in production of lipopolysaccharide (LPS), and impairment of intestinal barrier integrity. Increased levels of inflammatory markers like tumor necrosis factor alpha (TNF- α), interleukin-1 beta (IL-1 β), interleukin-6 (IL-6) and gut permeability markers (zonulin and fatty acid binding protein-2) were found in PD patients and were associated with the severity and duration of the disease. Dysbiosis of the gut microbiome was found to affect multiple pathways involved in the pathogenesis of PD through mechanistic insights. There is evidence that the vagus nerve plays a role in the propagation of misfolded α -synuclein from the gut to the brain. Further, a decreased production of neuroprotective metabolites such as butyrate and indole-3-propionic acid makes a contribution to neuroinflammation and dopaminergic neuronal loss. High-resolution functional validation was achieved using shotgun metagenomic studies which showed a downregulation of microbial pathways associated with SCFA biosynthesis and upregulation of pathways associated with inflammatory responses. Importantly, dysbiosis was found in prodromal conditions, such as idiopathic REM sleep behaviour disorder, indicating that dysbiosis is present prior to onset of motor symptoms. In general, the findings confirm the correlation between dysbiosis of the microbiota and PD, and its involvement in the disruption of the intestinal barrier, systemic inflammatory response and neurodegenerative .

CONCLUSION

In summary, gut microbiome is an important and complex player in the pathogenesis of PD via the gut-brain axis. The evidence that microbial dysbiosis is involved in the pathogenesis of α -synuclein pathology, neuroinflammation and metabolic disturbances is growing and all of these are implicated in dopaminergic neurodegeneration. Consistent microbial signatures and functional alterations in PD offer a solid basis for the development of novel diagnostic biomarkers, especially in early and/or prodromal stages of PD. The use of metagenomic technologies has also enabled a greater understanding of the function of the microbiota, including a high-resolution view, further supporting the mechanistic understanding of the gut-brain axis. These progressions notwithstanding, there are still some problems to solve such as variations across studies, confounding factors and establishing causality. In the future, further studies are needed to establish a time course and to develop standard methods and integrative multi-omics analysis to understand the association of dysbiosis and disease onset. Other novel therapies for PDs that have recently gained momentum are known as microbiomics therapy, such as psychobiotics and fecal microbiota transplant. They will need strong clinical trials to be translated into clinical practice and more knowledge about host-microbiome interactions. In sum, the study of the microbiome in the gut provides a novel and promising opportunity to understand the physiology, diagnosis and treatment of Parkinson disease from a new perspective, as a multi-organ disorder rather than a purely neurological one.”

DISCUSSION

In this thesis, I discuss the increasing evidence that the gut-brain axis is a key factor in the pathogenesis of Parkinson's disease. PD is regarded as a disorder primarily affecting the substantia nigra, but is now recognized as a systemic disorder with early pathological changes in the gastrointestinal tract. The “body-first” theory is a powerful model that suggests peripheral α -synuclein aggregation is responsible for central neurodegeneration through the vagus nerve. The changes in gut microbiome in PD patients are one of the most consistent results that have been observed in various studies. Decreases in the abundance of SCFA-producing bacteria, like *Faecalibacterium prausnitzii* and *Roseburia intestinalis*, indicate loss of anti-inflammatory and neuroprotective metabolites, specifically butyrate. This is significant for intestinal barrier integrity and immune regulation. However, the rise in pro-inflammatory bacteria (*Enterobacteriaceae*) supports the role of microbial induced inflammation in PD progression. The mechanisms are several that are interconnected. First, the loss of the normal microbial balance can lead to misfolding of α -synuclein in gut neurons by molecular mimicry or by bacterial amyloids. Second, translocated bacterial endotoxins like lipopolysaccharide (LPS) cause systemic inflammation and activation of microglial cells in the brain. Third, microbial metabolism disruption, in particular, SCFAs and tryptophan-derived metabolites, has an impact on neurotransmission, neuroinflammation and neuronal survival. The role of the kynurenine pathway is particularly interesting because an increase in its neurotoxic metabolites such as quinolinic acid could be responsible for excitotoxicity and loss of dopaminergic neurons. Likewise, serotonin production and signaling changes account for some of the early non-motor symptoms (depression and constipation). New technologies have greatly improved the knowledge of the functionality changes in the microbial community, particularly the shotgun metagenomics approach. These methods allow pathway-level analysis, providing insights into

changes in metabolic pathways, including pathways involved in SCFA biosynthesis, LPS production, and neurotransmitter pathways, which are not possible with 16S rRNA sequencing. But methodological variability, confounding factors (such as medication, diet, BMI), and the lack of standardization are significant challenges. Importantly, alteration of the microbiome has been seen in prodromal cohorts (e.g. idiopathic REM sleep behaviour disorder) before clinical PD. This provides opportunities for early diagnosis and intervention. But the cause of dysbiosis remains uncertain, as it could be a cause of PD, or a result of disease progression is still being explored. In terms of therapeutic potential, microbiome-targeted approaches, including probiotics, prebiotics, and fecal microbiota transplantation (FMT), hold promise for regulating inflammation and neurochemical processes. However, there is still a lack of clinical proof, and problems like strain specificity, safety and long-term efficacy need to be resolved before the widespread use of this approach.

REFERENCES

- [1] Parkinson's disease J. Dorsey and B. Bloem, "The Parkinson Pandemic—A Call to Action," *JAMA Neurology*, vol. 75, no. 1, pp. 9–10, 2018.
- [2] W. Poewe, K. Seppi, C. Tanner *et al.*, "Parkinson disease," *Nature Reviews Disease Primers*, vol. 3, no. 1, pp. 1–21, 2017.
- [3] H. Braak, K. Del Tredici, U. Rüb, R. de Vos, E. Jansen Steur, and E. Braak, "Staging of brain pathology related to sporadic Parkinson's disease," *Neurobiology of Aging*, vol. 24, no. 2, pp. 197–211, 2003.
- [4] F. Scheperjans, V. Aho, P. A. Pereira *et al.*, "Gut microbiota are related to Parkinson's disease and clinical phenotype," *Movement Disorders*, vol. 30, no. 3, pp. 350–358, 2015.
- [5] J. F. Cryan and T. G. Dinan, "Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour," *Nature Reviews Neuroscience*, vol. 13, no. 10, pp. 701–712, 2012.
- [6] G. Bonaz, V. Bazin, and A. Pellissier, "The vagus nerve at the interface of the microbiota-gut-brain axis," *Frontiers in Neuroscience*, vol. 12, p. 49, 2018.
- [7] A. Koh, F. De Vadder, P. Kovatcheva-Datchary, and F. Bäckhed, "From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites," *Cell*, vol. 165, no. 6, pp. 1332–1345, 2016.
- [8] L. Liu, T. A. U. Johnson, and H. J. Olsen, "Vagotomy and Parkinson disease risk: a Danish nationwide cohort study," *Annals of Neurology*, vol. 78, no. 4, pp. 522–529, 2017.
- [9] M. Yano, K. Yu, G. Donaldson *et al.*, "Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis," *Cell*, vol. 161, no. 2, pp. 264–276, 2015.

- [10] D. Aarsland, K. Brønnick, and A. Fladby, “Mild cognitive impairment in Parkinson’s disease,” *Current Neurology and Neuroscience Reports*, vol. 11, no. 4, pp. 371–378, 2011.
- [11] R. Schwarcz and J. P. Stone, “The kynurenine pathway and the brain: challenges, controversies and promises,” *Neuropharmacology*, vol. 112, pp. 237–247, 2017.
- [12] S. Dalile, L. Van Oudenhove, B. Vervliet, and K. Verbeke, “The role of short-chain fatty acids in microbiota–gut–brain communication,” *Nature Reviews Gastroenterology & Hepatology*, vol. 16, no. 8, pp. 461–478, 2019.
- [13] S. Forsyth, K. Shannon, J. H. Kordower *et al.*, “Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson’s disease,” *PLoS ONE*, vol. 6, no. 12, p. e28032, 2011.
- [14] M. Houser and M. Tansey, “The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis?” *NPJ Parkinson’s Disease*, vol. 3, no. 1, pp. 1–9, 2017.
- [15] V. Perry, J. Holmes, and C. Cunningham, “Systemic infections and inflammation affect chronic neurodegeneration,” *Nature Reviews Immunology*, vol. 7, no. 2, pp. 161–167, 2007.
- [16] M. Gershon, *The Second Brain*. New York, NY, USA: HarperCollins, 1998.
- [17] R. Shannon, J. Keshavarzian, H. Dodiya *et al.*, “Alpha-synuclein in colonic submucosa in early untreated Parkinson’s disease,” *Movement Disorders*, vol. 27, no. 6, pp. 709–715, 2012.
- [18] J. F. Cryan, K. J. O’Riordan, C. S. M. Cowan *et al.*, “The microbiota-gut-brain axis,” *Physiological Reviews*, vol. 99, no. 4, pp. 1877–2013, 2019.
- [19] G. Bonaz, “Vagus nerve and the gut-brain axis,” *Progress in Neurobiology*, vol. 160, pp. 1–17, 2018.
- [20] T. Dinan and J. Cryan, “Gut instincts: microbiota as a key regulator of brain development, ageing and neurodegeneration,” *Journal of Physiology*, vol. 595, no. 2, pp. 489–503, 2017.
- [21] M. Reigstad, K. Salmonson, J. F. Rainey *et al.*, “Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells,” *FASEB Journal*, vol. 29, no. 4, pp. 1395–1403, 2015.
- [22] A. Politis and P. Niccolini, “Serotonin in Parkinson’s disease,” *Behavioural Brain Research*, vol. 277, pp. 136–145, 2015.
- [23] L. Oxenkrug, “The extended life span of *Drosophila melanogaster* eye-color (white and vermilion) mutants with impaired formation of kynurenine,” *Journal of Neural Transmission*, vol. 117, no. 1, pp. 23–26, 2010.

- [24] S. Sampson, R. Debelius, T. Thron *et al.*, “Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease,” *Cell*, vol. 167, no. 6, pp. 1469–1480, 2016.
- [25] M. Block, L. Zecca, and J. Hong, “Microglia-mediated neurotoxicity: uncovering the molecular mechanisms,” *Nature Reviews Neuroscience*, vol. 8, no. 1, pp. 57–69, 2007.
- [26] M. Gershon and J. Tack, “The serotonin signaling system: from basic understanding to drug development for functional GI disorders,” *Gastroenterology*, vol. 132, no. 1, pp. 397–414, 2007.
- [27] H. Braak, U. Rüb, W. Gai, and K. Del Tredici, “Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen,” *Journal of Neural Transmission*, vol. 110, no. 5, pp. 517–536, 2003.
- [28] R. Shannon, J. Keshavarzian, H. Dodiya *et al.*, “Is alpha-synuclein in the colon a biomarker for premotor Parkinson’s disease? Evidence from 3 cases,” *Movement Disorders*, vol. 27, no. 6, pp. 716–719, 2012.
- [29] F. Scheperjans, V. Aho, P. Pereira *et al.*, “Gut microbiota are related to Parkinson’s disease and clinical phenotype,” *Movement Disorders*, vol. 30, no. 3, pp. 350–358, 2015.
- [30] T. Keshavarzian, S. Green, P. Engen *et al.*, “Colonic bacterial composition in Parkinson’s disease,” *Movement Disorders*, vol. 30, no. 10, pp. 1351–1360, 2015.
- [31] H. Sokol, P. Pigneur, L. Watterlot *et al.*, “Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients,” *Proceedings of the National Academy of Sciences USA*, vol. 105, no. 43, pp. 16731–16736, 2008.
- [32] S. Sampson, R. Debelius, T. Thron *et al.*, “Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease,” *Cell*, vol. 167, no. 6, pp. 1469–1480, 2016.
- [33] R. Perez-Pardo, H. Dodiya, P. Engen *et al.*, “Role of TLR4 in the gut-brain axis in Parkinson’s disease: a translational study from men to mice,” *Gut*, vol. 68, no. 5, pp. 829–843, 2019.
- [34] J. Houser and M. Tansey, “The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis?” *NPJ Parkinson’s Disease*, vol. 3, pp. 1–9, 2017.
- [35] T. Bedarf, F. Hildebrand, I. Coelho *et al.*, “Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson’s disease patients,” *Genome Medicine*, vol. 9, no. 1, pp. 1–13, 2017.
- [36] Akkermansia muciniphila M. Derrien, E. Vaughan, C. Plugge, and W. de Vos, “Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium,”

International Journal of Systematic and Evolutionary Microbiology, vol. 54, no. 5, pp. 1469–1476, 2004.

[37] F. Scheperjans, V. Aho, P. Pereira *et al.*, “Gut microbiota are related to Parkinson’s disease and clinical phenotype,” *Movement Disorders*, vol. 30, no. 3, pp. 350–358, 2015.

[38] T. Keshavarzian, S. Green, P. Engen *et al.*, “Colonic bacterial composition in Parkinson’s disease,” *Movement Disorders*, vol. 30, no. 10, pp. 1351–1360, 2015.

[39] C. Macfabe, “Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders,” *Microbial Ecology in Health and Disease*, vol. 23, no. 1, p. 19260, 2012.

[40] T. Bedarf, F. Hildebrand, I. Coelho *et al.*, “Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson’s disease patients,” *Genome Medicine*, vol. 9, no. 1, pp. 1–13, 2017.

[41] A. Wallen, C. Appah, A. Dean *et al.*, “Characterizing dysbiosis of gut microbiome in Parkinson’s disease in a large cohort,” *Nature Communications*, vol. 13, no. 1, pp. 1–17, 2022.

[42] A. Wallen, C. Appah, A. Dean *et al.*, “Functional and taxonomic alterations in the gut microbiome of Parkinson’s disease patients,” *Nature Communications*, vol. 13, no. 1, pp. 1–17, 2022.

[43] H. Braak and K. Del Tredici, “Neuropathological staging of brain pathology in sporadic Parkinson’s disease,” *Neurobiology of Aging*, vol. 24, no. 2, pp. 197–211, 2003.

[44] R. Shannon, J. Keshavarzian, H. Dodiya *et al.*, “Alpha-synuclein in colonic submucosa in early untreated Parkinson’s disease,” *Movement Disorders*, vol. 27, no. 6, pp. 709–715, 2012.

[45] G. Heinzl, K. Berg, C. Gasser *et al.*, “Update of the MDS research criteria for prodromal Parkinson’s disease,” *Movement Disorders*, vol. 34, no. 10, pp. 1464–1470, 2019.

[46] S. Forsyth, K. Shannon, J. H. Kordower *et al.*, “Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson’s disease,” *PLoS ONE*, vol. 6, no. 12, p. e28032, 2011.

[47] E. Chen, M. Brown, and D. St. Pierre, “Bacterial amyloids and their interactions with alpha-synuclein in Parkinson’s disease,” *Frontiers in Molecular Neuroscience*, vol. 9, pp. 1–14, 2016.

[48] S. Sampson, R. Debelius, T. Thron *et al.*, “Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease,” *Cell*, vol. 167, no. 6, pp. 1469–1480, 2016.

[49] M. Houser and M. Tansey, “The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis?” *NPJ Parkinson’s Disease*, vol. 3, no. 1, pp. 1–9, 2017.

- [50] C. Pellegrini, R. Antonioli, C. Colucci *et al.*, “Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases?” *Acta Neuropathologica*, vol. 136, no. 3, pp. 345–361, 2018.
- [51] V. Perry and C. Holmes, “Microglial priming in neurodegenerative disease,” *Nature Reviews Neurology*, vol. 10, no. 4, pp. 217–224, 2014.
- [52] M. Block, L. Zecca, and J. Hong, “Microglia-mediated neurotoxicity: uncovering the molecular mechanisms,” *Nature Reviews Neuroscience*, vol. 8, no. 1, pp. 57–69, 2007.
- [53] D. Sulzer and D. Surmeier, “Neuronal vulnerability, pathogenesis, and Parkinson’s disease,” *Movement Disorders*, vol. 28, no. 1, pp. 41–50, 2013.
- [54] E. St. Laurent, M. O’Brien, and C. Ahmad, “Butyrate, neuroepigenetics and Parkinson’s disease,” *Neurochemistry International*, vol. 122, pp. 1–10, 2019.
- [55] D. Cani and P. Knauf, “How gut microbes talk to organs: the role of endocrine and nervous routes,” *Molecular Metabolism*, vol. 44, p. 101025, 2021.
- [56] S. Dalile, L. Van Oudenhove, B. Vervliet, and K. Verbeke, “The role of short-chain fatty acids in microbiota–gut–brain communication,” *Nature Reviews Gastroenterology & Hepatology*, vol. 16, no. 8, pp. 461–478, 2019.
- [57] A. Silva, R. Bernardi, and M. Frozza, “The role of short-chain fatty acids from gut microbiota in gut-brain communication,” *Frontiers in Endocrinology*, vol. 11, p. 25, 2020.
- [58] C. MacFabe, “Autism: metabolism, mitochondria, and the microbiome,” *Global Advances in Health and Medicine*, vol. 2, no. 6, pp. 52–66, 2013.
- [59] T. Bedarf, F. Hildebrand, I. Coelho *et al.*, “Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson’s disease patients,” *Genome Medicine*, vol. 9, no. 1, pp. 1–13, 2017.
- [60] Parkinson's disease A. Singleton and M. Farrer, “Genetics of Parkinson’s disease: risk and pathways,” *Nature Reviews Genetics*, vol. 14, no. 11, pp. 768–781, 2013.
- [61] M. Gardet, A. Benita, X. Li *et al.*, “LRRK2 is involved in the IFN- γ response and host response to pathogens,” *Journal of Immunology*, vol. 185, no. 9, pp. 5577–5585, 2010.
- [62] J. Bedarf, A. Nalls, and D. Hernandez, “Interactions between LRRK2 and gut microbiota in Parkinson’s disease,” *Movement Disorders*, vol. 35, no. 2, pp. 239–250, 2020.
- [63] E. Bullich, S. Keshavarzian, and A. Fasano, “GBA1 mutations and gut microbiome composition in Parkinson’s disease,” *NPJ Parkinson’s Disease*, vol. 5, no. 1, pp. 1–9, 2019.
- [64] N. Quince, A. Walker, J. Simpson, N. Loman, and N. Segata, “Shotgun metagenomics, from sampling to analysis,” *Nature Biotechnology*, vol. 35, no. 9, pp. 833–844, 2017.

- [65] J. F. Cryan, K. J. O’Riordan, C. S. M. Cowan *et al.*, “The microbiota-gut-brain axis,” *Physiological Reviews*, vol. 99, no. 4, pp. 1877–2013, 2019.
- [66] T. G. Dinan, C. Stanton, and J. F. Cryan, “Psychobiotics: a novel class of psychotropic,” *Biological Psychiatry*, vol. 74, no. 10, pp. 720–726, 2013.
- [67] Parkinson's disease S. Sarkar, S. Banerjee, and P. Ghosh, “Psychobiotics and the gut-brain axis: in the pursuit of happiness,” *Neuropsychiatric Disease and Treatment*, vol. 12, pp. 715–723, 2016.
- [68] A. M. Morshedi, K. Hashemi, and R. Moazzen, “Probiotics and neuroinflammation: mechanisms and therapeutic perspectives,” *Frontiers in Neuroscience*, vol. 15, p. 662146, 2021.
- [69] H. Liu, J. Wang, T. He *et al.*, “Probiotics for treatment of autism spectrum disorder: a systematic review and meta-analysis,” *Nutrients*, vol. 11, no. 8, p. 1797, 2019.
- [70] S. Severance, R. Gressitt, and R. Yolken, “Probiotic normalization of *Candida albicans* in schizophrenia: a randomized, placebo-controlled, longitudinal pilot study,” *Brain, Behavior, and Immunity*, vol. 62, pp. 41–45, 2017.
- [71] G. Gibson and M. Roberfroid, “Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics,” *The Journal of Nutrition*, vol. 125, no. 6, pp. 1401–1412, 1995.
- [72] P. Schmidt, N. Cowen, C. Harmer *et al.*, “Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers,” *Psychopharmacology*, vol. 232, no. 10, pp. 1793–1801, 2015.
- [73] Y. Wang, L. Li, J. Chen *et al.*, “Prebiotics attenuate autism-like behaviors in valproic acid-induced mouse model by restoring gut microbiota and immune balance,” *Brain, Behavior, and Immunity*, vol. 88, pp. 499–512, 2020.
- [74] M. Cammarota, G. Ianiro, H. Tilg *et al.*, “European consensus conference on faecal microbiota transplantation in clinical practice,” *Gut*, vol. 66, no. 4, pp. 569–580, 2017.
- [75] E. Allegretti, J. Mullish, J. Kelly, and M. Fischer, “The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications,” *The Lancet*, vol. 394, no. 10196, pp. 420–431, 2019.
- [76] J. DeFilipp, Y. Bloom, T. Soto *et al.*, “Drug-resistant *E. coli* bacteremia transmitted by fecal microbiota transplant,” *New England Journal of Medicine*, vol. 381, no. 21, pp. 2043–2050, 2019.
- [77] DNA Genotek C. Choo, J. Leong, and A. Rogers, “Sample storage conditions significantly influence faecal microbiome profiles,” *Scientific Reports*, vol. 5, no. 1, pp. 1–10, 2015.

- [78] J. Carroll, C. Ringel-Kulka, Y. Siddle, and J. Klaenhammer, “Characterization of the fecal microbiota using high-throughput sequencing reveals stability during storage,” *Applied and Environmental Microbiology*, vol. 78, no. 18, pp. 6578–6581, 2012.
- [79] D. Song, A. Tapia, and K. Schirmer, “Evaluation of fecal collection and storage methods for metagenomic studies,” *BMC Microbiology*, vol. 16, no. 1, pp. 1–12, 2016.
- [80] J. Nicholson, E. Holmes, J. Kinross *et al.*, “Host-gut microbiota metabolic interactions,” *Science*, vol. 336, no. 6086, pp. 1262–1267, 2012.
- [81] QIAGEN A. Costea, F. Zeller, S. Sunagawa *et al.*, “Towards standards for human fecal sample processing in metagenomic studies,” *Nature Biotechnology*, vol. 35, no. 11, pp. 1069–1076, 2017.
- [82] A. Costea, F. Hildebrand, M. Arumugam *et al.*, “Enterotypes in the landscape of gut microbial community composition,” *Nature Microbiology*, vol. 3, no. 1, pp. 8–16, 2018.
- [83] J. Bravo, P. Forsythe, M. Chew *et al.*, “Ingestion of *Lactobacillus* strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve,” *Proceedings of the National Academy of Sciences USA*, vol. 108, no. 38, pp. 16050–16055, 2011.
- [84] M. Olm, C. Crits-Christoph, L. Bouma-Gregson *et al.*, “inStrain profiles population microdiversity from metagenomic data and sensitively detects shared microbial strains,” *Nature Biotechnology*, vol. 39, no. 6, pp. 727–736, 2021.
- [85] C. Sieber, A. Probst, A. Sharrar *et al.*, “Recovery of genomes from metagenomes via a dereplication, aggregation and scoring strategy,” *Nature Microbiology*, vol. 3, no. 7, pp. 836–843, 2018.
- [86] D. Parks, M. Imelfort, C. Skennerton, P. Hugenholtz, and G. Tyson, “CheckM: assessing the quality of microbial genomes recovered from isolates, single cells, and metagenomes,” *Genome Research*, vol. 25, no. 7, pp. 1043–1055, 2015.
- [87] M. Kanehisa, Y. Sato, and K. Morishima, “BlastKOALA and GhostKOALA: KEGG tools for functional characterization of genome and metagenome sequences,” *Journal of Molecular Biology*, vol. 428, no. 4, pp. 726–731, 2016.
- [88] J. Lin and S. Peddada, “Analysis of compositions of microbiomes with bias correction,” *Nature Communications*, vol. 11, no. 1, pp. 1–11, 2020.
- [89] K. Rohart, B. Gautier, A. Singh, and K. Lê Cao, “mixOmics: an R package for ‘omics feature selection and multiple data integration,” *PLoS Computational Biology*, vol. 13, no. 11, p. e1005752, 2017.

LIST OF PUBLICATIONS

1.Review Paper

Title of paper - **"MICROBIOME-DRIVEN NEUROBIOLOGY TO UNDERSTANDING OF THE GUT-BRAIN COMMUNICATION NETWORK"**

Author Names- Huda khanam and Dr. Kriti Bhandari

Name of the Journal - "International Journal of Innovative Science and Research Technology"

Date of submission – 15 April, 2026

Indexing – Google Scholar, ResearchGate, Semantic Scholar, and SJIFactor.com

Status of paper – Accepted

Date of Acceptance – 6 May, 2026



INTERNATIONAL JOURNAL OF INNOVATIVE SCIENCE AND RESEARCH TECHNOLOGY

IJISRT A DIGITAL LIBRARY

AUTHOR CERTIFICATE

THIS IS TO CERTIFY THAT THE MANUSCRIPT, TITLED
Microbiome-Driven Neurobiology to Understanding of the Gut-Brain
Communication Network

AUTHORED BY
Huda Khanam

HAS BEEN PUBLISHED IN
Volume 11 | Issue 5 | May-2026

ARTICLE DIGITAL NO.
IJISRT26MAY280



EDITOR IN CHIEF IJISRT

WWW.IJISRT.COM

This document certifies that the manuscript listed above was submitted by above said respected author
To verify the submitted manuscript please visit our official website: www.ijisrt.com
Or Email us: editor@ijisrt.com

Paper Acceptance Notification for Paper ID "IJISRT26MAY280"



Inbox



Ijisrt digital li... 6 May

to me, ijisrt ✓



Hello Author ,

Greetings of the day

Paper ID: "IJISRT26MAY280"

**Paper Title: "MICROBIOME-DRIVEN NEUROBIOLOGY
TO UNDERSTANDING OF THE GUT-BRAIN
COMMUNICATION NETWORK"**

Congratulations.....

We are happy to inform you that your research paper has been "Accepted" for publishing in "International Journal of Innovative Science and Research Technology". After completion of the registration processes, your research paper will be available on IJISRT official website in Volume 11 - 2026 - Issue 5 - May.



Page 1 of 35 - Cover Page

Submission ID trn:oid::3618:141650553

Huda khanam.docx

NUSRL, Ranchi

Document Details

Submission ID

trn:oid::3618:141650553

Submission Date

Jun 4, 2026, 12:03 PM GMT+5:30

Download Date

Jun 4, 2026, 12:08 PM GMT+5:30

File Name

Huda khanam.docx

File Size

213.3 KB

30 Pages

10,384 Words

63,250 Characters



Page 1 of 35 - Cover Page

Submission ID trn:oid::3618:141650553



Page 2 of 35 - Integrity Overview

Submission ID trn:oid::3618:141650553

4% Overall Similarity

The combined total of all matches, including overlapping sources, for each database.

Filtered from the Report

- Bibliography
- Quoted Text
- Cited Text

Match Groups

- 43 Not Cited or Quoted 4%**
Matches with neither in-text citation nor quotation marks
- 0 Missing Quotations 0%**
Matches that are still very similar to source material
- 0 Missing Citation 0%**
Matches that have quotation marks, but no in-text citation
- 0 Cited and Quoted 0%**
Matches with in-text citation present, but no quotation marks

Top Sources

- 2% Internet sources
- 2% Publications
- 2% Submitted works (Student Papers)

Integrity Flags

0 Integrity Flags for Review

No suspicious text manipulations found.

Our system's algorithms look deeply at a document for any inconsistencies that would set it apart from a normal submission. If we notice something strange, we flag it for you to review.

A Flag is not necessarily an indicator of a problem. However, we'd recommend you focus your attention there for further review.



DELHI TECHNOLOGICAL UNIVERSITY

(Formerly Delhi college of Engineering)

Shahbad Daulatpur, Main Bawana Road, Delhi-42

PLAGIARISM VERIFICATION

Title of Thesis “ **Investigating the Gut–Brain Interaction in Parkinson's Disease: Neuroinflammation, Microbiome Dysbiosis, and Therapeutic Intervention**” Total Pages 30
Name of the scholar **Huda** (24/MSCBIO/60).

Supervisor

Dr. Kriti Bhandari

Department of Biotechnology

This is to report that the above thesis was scanned for similarity detection. Process and outcome is given below :

Software used: **Turnitin**, Similarity Index: **3%**, Total Word Count: **10,384**

Date:

Candidate's Signature

Supervisor's Signature

Huda Khanam

 +8076688069

 hudarajput890@gmail.com

EDUCATION

- Aug 2024 – Jun 2025(Expected)
M.Sc. Biotechnology, Delhi Technological University
- Nov. 2021- Jun 2024
B.Sc. Life Science , Indira Gandhi national Open University

Skills and Interests

- .
- Skilled in communication, teamwork and academic presentation with the ability to work efficiently in both individual and group environments.
- Possess strong problem-solving abilities, time management skills and adaptability in learning new scientific concepts and laboratory techniques.
- Proficient in MS Word, PowerPoint, scientific documentation and basic computational tools used in biotechnology studies.
- Interested in biotechnology, molecular biology, genetics, microbiology and computational biology with a keen enthusiasm for scientific innovation and modern healthcare technologies.

Undertaking

I am taking full responsibilities of this project work and thesis written for my dissertation. This thesis is neither copied from any place or written AI/Chat GPT assisted manner. In case of any discrepancies and falsified information my degree may be cancelled.

I will take responsibilities of the dissertation if something found wrong take any appropriate action.

Name of Student

Roll.No.

Signature